Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies

Lenalidomide in combination with dexamethasone is recommended, within its licensed indication, as an option for the treatment of multiple myeloma only in people who have received 2 or more prior therapies. It is recommended only if the company provides lenalidomide according to the commercial arrangement.

People currently receiving lenalidomide for the treatment of multiple myeloma, but who have not received 2 or more prior therapies, should have the option to continue therapy until they and their clinicians consider it appropriate to stop.